Aligos Therapeutics
Nasdaq ALGS · South San Francisco, CA
Works in GI & liver · Infectious disease · Respiratory
Aligos Therapeutics is a clinical trial sponsor based in South San Francisco, CA, listed as Nasdaq ALGS. It has 2 active clinical trials with 224 planned participants, in GI & liver, Infectious disease and Respiratory. Since 2021 it has completed 10 trials and stopped 3 early.
Trial track record · since 2021
Financials · Nasdaq ALGS
Fundraising
Pipeline · 2 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about Aligos Therapeutics
Aligos Therapeutics is lead sponsor of 2 active clinical trials on ClinicalTrials.gov, with 224 planned participants, in GI & liver, Infectious disease, Respiratory. Since 2021 it has completed 10 trials and stopped 3 early.
Aligos Therapeutics is based in South San Francisco, CA and is listed as Nasdaq ALGS. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Aligos Therapeutics; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-09-11.
Approve Suite is not affiliated with Aligos Therapeutics.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.